What type of study is this?

Healthcare Resource Use, Healthcare Costs, and Unmet Needs Among Patients Treated for EGFR-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

View Full Paper

Ask AI

Bookmark

Authors

Observational analysis reports costs and resource use in EGFRm advanced NSCLC patients, suggesting critical unmet needs.

Each successive line of therapy resulted in increased healthcare costs and reduced duration of treatment.
Patients initiating first-line osimertinib had average costs of $27,610, which increased significantly in second and third-line therapies.
The analysis highlighted that 41.6% of patients progressed to the second line, with subsequent costs averaging $28,971 in the second line.
Mean outpatient visits were over four per month, particularly pronounced in the first-line osimertinib subgroup, reflecting significant healthcare resource use.

Waterhouse et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Observational analysis reports costs and resource use in EGFRm advanced NSCLC patients, suggesting critical unmet needs.

Each successive line of therapy resulted in increased healthcare costs and reduced duration of treatment.
Patients initiating first-line osimertinib had average costs of $27,610, which increased significantly in second and third-line therapies.
The analysis highlighted that 41.6% of patients progressed to the second line, with subsequent costs averaging $28,971 in the second line.
Mean outpatient visits were over four per month, particularly pronounced in the first-line osimertinib subgroup, reflecting significant healthcare resource use.

Waterhouse et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark